Mak­er of world's most ex­pen­sive pre­scrip­tion drug flash­es PhI­II da­ta for a po­ten­tial fourth prod­uct

Three years be­fore they be­came own­ers of the most ex­pen­sive drug in the coun­try, Am­ryt be­gan its cor­po­rate life around a sin­gle ther­a­py picked up from a small Ger­man drug­mak­er called Birken: Episal­van, an EMA-ap­proved drug for par­tial thick­ness wounds. They hoped to de­vel­op it as an or­phan drug for a con­di­tion called epi­der­mol­y­sis bul­losa, where a pa­tient’s skin be­comes as frag­ile as but­ter­fly wings. They put it al­most im­me­di­ate­ly in­to a Phase III study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER